Condition
HLA Antibodies
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06921239RecruitingPrimary
HLA Antibodies in Systemic Lupus Erythematosus
NCT07316829Active Not Recruiting
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
Showing all 2 trials